Centenarians’ offspring are 42% less likely to die at any given age compared to peers whose parents had shorter lifespans, according to a study published in JAMA Network Open and covered by Medscape. Researchers followed 2,319 offspring of centenarians alongside a control group of 2,703 individuals across three distinct populations for up to 29 years to determine whether disease resistance passes across generations.
Three Cohorts Tracked for Nearly Three Decades
The study drew data from the LonGenity study following an Ashkenazi Jewish population in the Bronx, New York, the New England Centenarian Study, and the UK Biobank, where outcomes derived from linked national health records. Investigators compared adults with at least one parent who reached 100 or older against the control group.
At any given age, the centenarians’ offspring showed a 33% lower risk of developing cardiovascular disease and a 32% lower risk of hypertension. When those conditions did develop, they arrived later—about 3 years later for death and 5 years later for hypertension. According to Sofiya Milman, MD, who serves as a professor of medicine and genetics and directs Human Longevity Studies at the Albert Einstein School of Medicine in the Bronx, the hazard ratios remained virtually unchanged even after investigators controlled for smoking, diet, physical activity, alcohol consumption, educational attainment, and socioeconomic standing.
Why Offspring Offer Clearer Answers Than Centenarians
Studying centenarians directly presents inherent difficulties because researchers cannot easily determine whether observed biological traits protected the individual or simply marked extreme old age. By the time someone reaches 100, most of their birth cohort has died, leaving no matched comparison group.
Studying offspring bypasses these hurdles. They share half their genome with a centenarian parent, remain young enough to have living peers, and can be followed forward in time. Prior milestones include a 2004 report from the New England Centenarian Study showing a 62% lower all-cause mortality and 85% lower coronary heart disease mortality in centenarians’ offspring, and a 2017 finding from the LonGenity cohort confirming lower cardiovascular disease prevalence. Joris Deelen, PhD, noted that incorporating three different populations was useful. Because about half of the offspring group may not have inherited the protective variants, Deelen pointed out that the 42% reduction figure likely dilutes the true strength of the genetic signal.
The Unexpected Exception of Cancer Risk
Despite lower mortality and cardiometabolic protection, cancer rates among centenarians’ offspring matched those of the control group. Milman admitted surprise at this finding. She suggested that over-screening in healthy older adults might uncover indolent thyroid and prostate subtypes that would never have caused symptoms or death.
Jalees Rehman, MD, who directs biochemistry and molecular genetics at the University of Illinois College of Medicine located in Chicago, put forward a vascular rationale for the findings.
Differing Views on Molecular Pathways and Drug Development
Milman’s team at Albert Einstein College of Medicine focuses on the growth hormone and insulin-like growth factor 1 (IGF-1) pathway. Following 2008 discoveries of IGF-1 receptor mutations and 2014 findings that lower circulating IGF-1 predicted survival, Milman explained that a biological switch occurs around age 50 where lower growth hormone levels become beneficial. Dr. Milman disclosed that she holds an application for a patent regarding pegylated growth hormone receptor antagonists intended for aging and Alzheimer’s disease management.
Deelen questioned whether IGF-1 evidence is sufficiently strong without functional testing in living systems. Rehman emphasized inflammation and immune regulation networks mediated by healthy endothelium.
Common Questions About Centenarian Offspring
* How much lower is the mortality risk for centenarians’ offspring?
At any given age, centenarians’ offspring are 42% less likely to die compared to a control group, according to the Medscape report on the JAMA Network Open study.
* Do centenarians’ offspring have a lower risk of cancer?
No, the study found that cancer incidence in centenarians’ offspring showed no difference compared to the control group.
* What biological pathway do researchers at Albert Einstein College of Medicine focus on?
Researchers investigate the growth hormone and insulin-like growth factor 1 (IGF-1) pathway, noting that reduced signaling through this pathway appears beneficial later in life.
* What populations were included in the recent study?
The study evaluated 2,319 centenarians’ offspring and 2,703 controls drawn from an Ashkenazi Jewish population in the Bronx, the New England Centenarian Study, and the UK Biobank.
Worth a look